Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29911750)

  • 1. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma.
    Shendy K; Abdelkawy K; Ali AA; Belal F; Abdelhakiem M; Magdy G; Anber N; Elbarbry F
    Xenobiotica; 2024 Feb; 54(2):95-105. PubMed ID: 38381003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the
    Guo Q; Sun JL; Li R; Li X
    Int J Gen Med; 2024; 17():1221-1231. PubMed ID: 38559593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.
    Holmboe L; Andersen AM; Mørkrid L; Slørdal L; Hall KS
    Br J Clin Pharmacol; 2012 Jan; 73(1):106-14. PubMed ID: 21707700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
    Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
    Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
    Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
    Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
    Reiss SN; Buie LW; Adel N; Goldman DA; Devlin SM; Douer D
    Ann Hematol; 2016 Dec; 95(12):2009-2015. PubMed ID: 27542957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Chen X; Li J; Yu L; Hu W; Cai J; Wang Z; Chen C; Zhang X; Xie Y; Wu K; Mo Y; Chen J; Shen S
    Br J Haematol; 2024 Apr; 204(4):1354-1366. PubMed ID: 38432257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors associated with high-dose methotrexate induced toxicities.
    Li W; Mo J; Yang Z; Zhao Z; Mei S
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):263-274. PubMed ID: 38501267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors.
    Campagne O; Huang J; Lin T; Reddick WE; Selvo NS; Onar-Thomas A; Ward D; Robinson G; Gajjar A; Stewart CF
    Eur J Pharm Sci; 2024 Feb; 193():106669. PubMed ID: 38070781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform
    Taylor ZL; Miller TP; Poweleit EA; DeGroote NP; Pommert L; Awoniyi O; Board SG; Ugboh N; Joshi V; Ambrosino N; Chavana A; Bernhardt MB; Schafer ES; O'Brien MM; Castellino SM; Ramsey LB
    Clin Transl Sci; 2023 Nov; 16(11):2130-2143. PubMed ID: 37503924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.
    Larkin T; Kashif R; Elsayed AH; Greer B; Mangrola K; Rafiee R; Nguyen N; Shastri V; Horn B; Lamba JK
    JCO Precis Oncol; 2023 Mar; 7():e2200580. PubMed ID: 36952646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Gut Microbiota Changes on Methotrexate-Induced Neurotoxicity in Developing Young Rats.
    Chen YC; Hou CY; Hsu MH; Huang LT; Hsiao CC; Sheen JM
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate Toxicity in Dermatological Patients.
    Ayén-Rodríguez Á; Gil-Villalba A; Ruiz-Villaverde R; Navarro-Triviño FJ
    Actas Dermosifiliogr; 2024 Feb; ():. PubMed ID: 38373610
    [No Abstract]   [Full Text] [Related]  

  • 15. [[Translated article]]Methotrexate Toxicity in Dermatological Patients.
    Rodríguez ÁA; Villalba AG; Villaverde RR; Navarro-Triviño FJ
    Actas Dermosifiliogr; 2024 May; ():. PubMed ID: 38815680
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis.
    Yao P; He X; Zhang R; Tong R; Xiao H
    Hematology; 2019 Dec; 24(1):10-19. PubMed ID: 30024839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
    Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
    Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of
    Razali RH; Noorizhab MNF; Jamari H; James RJ; Teh KH; Ibrahim HM; Teh LK; Salleh MZ
    Pediatr Hematol Oncol; 2020 Apr; 37(3):185-197. PubMed ID: 31870219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.
    Esmaili MA; Kazemi A; Faranoush M; Mellstedt H; Zaker F; Safa M; Mehrvar N; Rezvany MR
    Iran J Basic Med Sci; 2020 Jun; 23(6):800-809. PubMed ID: 32695297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.
    Frosst P; Blom HJ; Milos R; Goyette P; Sheppard CA; Matthews RG; Boers GJ; den Heijer M; Kluijtmans LA; van den Heuvel LP
    Nat Genet; 1995 May; 10(1):111-3. PubMed ID: 7647779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.